Literature DB >> 16620835

Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans.

Anders Vik1, Ellisiv B Mathiesen, Ann-Trude W Notø, Baldur Sveinbjørnsson, Jan Brox, John-Bjarne Hansen.   

Abstract

Osteoprotegerin (OPG) is a member of the tumour necrosis factor superfamily involved in the regulation of bone metabolism and vascular calcification. High serum values of OPG are associated with cardiovascular disease in humans. The purpose was to investigate serum OPG levels in subclinical carotid atherosclerosis and the relation between OPG levels and plaque morphology. OPG levels were compared in 29 persons with echogenic carotid plaques, 30 persons with echolucent plaques and 41 persons without carotid plaques, all recruited from a population health study. Computerized assessment of plaque echogenicity was done by use of the gray scale median (GSM). Participants with echogenic carotid plaques had lower serum OPG level (1.23 ng/ml; 1.02-1.48) (geometric mean; 95% CI) than persons with echolucent plaques (1.76 ng/ml; 1.46-2.14) and those without plaques (1.89 ng/ml; 1.60-2.21). OPG and PTH were independently related to GSM. A significant trend for decrease in GSM across quartiles of OPG was found (p=0.003) which remained significant even after adjustment for PTH and smoking. The present study demonstrates lower serum OPG levels in persons with subclinical echogenic carotid plaques and identified an inverse relation between serum OPG and plaque echogenicity. The findings support the concept that OPG may play an important role in arterial calcification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16620835     DOI: 10.1016/j.atherosclerosis.2006.03.002

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Bone mass density and bone metabolism marker are associated with progression of carotid and cardiac calcified plaque in Chinese elderly population.

Authors:  D Liu; L Chen; S Dong; Z Peng; H Yang; Y Chen; L Li; H Zhou; R Zhou
Journal:  Osteoporos Int       Date:  2019-06-10       Impact factor: 4.507

2.  Physical exercise, fitness and dietary pattern and their relationship with circadian blood pressure pattern, augmentation index and endothelial dysfunction biological markers: EVIDENT study protocol.

Authors:  Luis García-Ortiz; José I Recio-Rodríguez; Carlos Martín-Cantera; Alfredo Cabrejas-Sánchez; Amparo Gómez-Arranz; Natividad González-Viejo; Eguskiñe Iturregui-San Nicolás; Maria C Patino-Alonso; Manuel A Gómez-Marcos
Journal:  BMC Public Health       Date:  2010-05-06       Impact factor: 3.295

3.  Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study.

Authors:  M Kyla Shea; Sarah L Booth; Joseph M Massaro; Paul F Jacques; Ralph B D'Agostino; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Sekar Kathiresan; John F Keaney; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am J Epidemiol       Date:  2007-11-15       Impact factor: 4.897

4.  Delayed metabolism of postprandial triglyceride-rich lipoproteins in subjects with echolucent carotid plaques.

Authors:  Ann-Trude With Notø; Ellisiv Bøgeberg Mathiesen; Jan Brox; Johan Björkegren; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-03-05       Impact factor: 1.880

5.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

6.  The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis.

Authors:  John-Bjarne Hansen; José A Fernández; Ann-Trude With Notø; Hiroshi Deguchi; Johan Björkegren; Ellisiv B Mathiesen
Journal:  J Lipids       Date:  2011-07-06

7.  Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.

Authors:  Weena J Y Chen; Luuk J Rijzewijk; Rutger W van der Meer; Martijn W Heymans; Eelco van Duinkerken; Mark Lubberink; Adriaan A Lammertsma; Hildo J Lamb; Albert de Roos; Johannes A Romijn; Jan W A Smit; Jeroen J Bax; Mette Bjerre; Jan Frystyk; Allan Flyvbjerg; Michaela Diamant
Journal:  Cardiovasc Diabetol       Date:  2011-07-19       Impact factor: 9.951

8.  Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Authors:  J-J Body; P Bergmann; S Boonen; J-P Devogelaer; E Gielen; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-02-04       Impact factor: 4.507

9.  No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.

Authors:  Rolf Jorde; Monica Sneve; Peter A Torjesen; Yngve Figenschau; John-Bjarne Hansen; Guri Grimnes
Journal:  Nutr J       Date:  2010-01-07       Impact factor: 3.271

10.  The ApoC-I content of VLDL particles is associated with plaque size in persons with carotid atherosclerosis.

Authors:  Ann-Trude With Notø; Ellisiv Bøgeberg Mathiesen; Jan Brox; Johan Björkegren; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-05-29       Impact factor: 1.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.